Articles tagged with Cancer Cells
Researchers discovered a tension-sensitive molecule, Stu2, that ensures correct chromosome distribution during cell division. This 'fail safe' mechanism helps prevent aneuploidy, a genetic abnormality common in tumor cells.
A recent study has shown that combining radiation therapy with an immune system-strengthening compound can increase the immune response against tumors, even those outside the radiation field. This breakthrough could lead to longer treatment durations and reduced side effects, as well as new curative options for patients.
A study by University of Minnesota researchers reveals a pathway that enables cancer cells to tolerate faulty DNA replication, potentially leading to new anti-cancer therapies. The discovery was made possible by the development of a tool to analyze protein regulation triggered by DNA errors.
A clinical trial has shown that 27 of 29 advanced leukemia patients went into remission after their T cells were genetically engineered to fight cancer. The therapy, known as CAR T-cell therapy, uses a synthetic receptor molecule to empower the T cells to recognize and kill cancer cells.
Alterations in chromatin structure are essential for cancer development, accelerating cell cycle progression and malignant transformation. Changes in epigenetic factors and histone variants confer to cancer cells the ability to reprogram their genomes.
Researchers at UT Knoxville have discovered a novel regulatory pattern for cytokinesis, the final stage of cell division, triggered by the signaling protein Cdc42. This finding has implications for understanding cancer and other diseases, where defects in Cdc42 control are associated.
Using a simple circuit pattern with three electrodes, researchers assign unique digital identification numbers to each cell passing through the channels on the microfluidic chip. This technique captures information about cell sizes and movement speeds, allowing for automated counting and analysis of cells sorted on the chip.
A biomarker associated with basal cell carcinoma, EZH2, has been identified in a study published in JAMA Oncology. Higher levels of EZH2 and Ki67 were found in more aggressive tumors, suggesting that the protein may serve as a marker for increased cancer recurrence or tumor aggressiveness.
Researchers at Fred Hutchinson Cancer Center are developing engineered T cells to recognize and attack cancer cells. Preliminary data from a clinical trial shows promising results in treating acute myeloid leukemia, with patients experiencing stable disease and significant tumor regression. Next-generation strategies aim to improve ant...
In a clinical trial, half of 25 patients with Merkel cell carcinoma experienced substantial tumor shrinkage lasting nearly three times as long as conventional chemotherapy. Several patients had no remaining evidence of disease. The results suggest that immunotherapy drugs may be effective for other virus-associated cancers.
Researchers developed Monovar to analyze multiple single cells, detecting subtle DNA changes that can inform personalized medicine and cancer care. The method shows promise for diagnosing and treating various diseases, including pre-natal genetic diagnosis.
Scientists have identified a mechanism behind pancreatic cancer's resistance to certain drugs and found a way to block it, making the cancer susceptible to formerly ineffective therapies. By targeting a protein called HuR, researchers can revive abandoned drugs and develop more effective combination therapies.
Researchers at EMBL have determined the structure of the nuclear pore complex's inner ring, a crucial component in controlling molecular traffic to the cell's nucleus. The discovery brings the nuclear pore into focus and holds potential implications for understanding its role in cancer and aging.
Researchers at UT Southwestern Medical Center identified molecular ties between cancer cell growth and heart cell enlargement, potentially leading to repurposed cancer treatments for heart disease. The study found that inhibiting enzymes called HDACs can blunt excess heart muscle cell growth and slow the spread of cancer.
Researchers at Queen Mary University of London have developed a modified flu virus that can re-sensitize resistant pancreatic cancer cells to chemotherapy. The virus enhances the efficacy of the drug by preventing cancer cells from repairing themselves, leading to increased cell killing with lower doses.
A new study reveals how cancer cells turn healthy cells to the 'dark side' by using a mutant KRAS gene to release unique growth signals. This discovery could open up new approaches to cancer treatment by understanding the communication loop between cancer-causing genes and healthy stromal cells.
Researchers at the University of Missouri have discovered a compound that not only lowers cholesterol but also kills prostate cancer cells. The study found that the compound, initially developed as a cholesterol-fighting molecule, reduced prostate cancer cell growth and caused cancer cell death in human and mouse models.
Researchers at Umeå University found that mutations in the SAMHD1 protein lead to an imbalance of DNA building blocks and increased mutation rates in colon cancer cells. This discovery suggests that changes in dNTP levels may contribute to the development of colon cancer.
Researchers have identified six newly discovered proteins that may help prevent diabetes, Alzheimer's disease, cancer, and other age-related illnesses. The tiny proteins are produced in the mitochondria of cells and play a significant role in metabolism and cell survival.
Chronic lymphocytic leukemia (CLL) researchers have improved their models of the disease by understanding how cancer cells differentiate into antibody-secreting plasma cells in mice. Patient-derived T cells play a crucial role in this process, and therapies promoting differentiation may offer new treatment options for CLL.
Researchers at CRI identified a new metabolic pathway that allows cancer cells to survive in conditions toxic to normal cells. The study reveals that cancer cells use an alternate version of the pentose phosphate pathway and the Krebs cycle to defend against reactive oxygen species.
Two drugs, Vismodegib and Sonidegib, target the Hedgehog pathway to treat basal cell carcinoma, a common skin cancer affecting nearly 2.8 million Americans annually. The FDA-approved treatments have shown promise in shrinking tumors and improving response rates.
Researchers at VIB have discovered that killed tumor cells can be used as a vaccine to stimulate the immune system to prevent cancer cell growth. This finding opens up new perspectives for using necroptosis in immunotherapy and screening for cancer drugs that induce this type of immunogenic cell death.
Researchers at Washington University in St. Louis discovered that cancer cells can synthesize lipids from non-glucose sources, contradicting the long-held glucose hypothesis. This finding raises questions about diagnostic methods and treatment strategies for cancer.
Cells have evolved several tactics to cope with DNA lesions and replication stress, including fork repriming, fork reversal, and replisome dynamics. Improper repair of DNA lesions can lead to mutations and genetic abnormalities.
Researchers found that cancer cells have a resilient ability to repair nuclear envelope rupture during cell migration, but this process compromises genomic integrity. The study highlights a potential weakness in metastatic cancer cells and an opportunity for developing novel anti-metastatic drugs.
Researchers at Lomonosov Moscow State University found that heat shock triggers DNA damage response, leading to cellular senescence. The study's results may help develop new methods for curing cancer.
Researchers at the University of Georgia have created a new therapeutic for prostate cancer that has shown great efficacy in mouse models. The treatment, which involves packaging and administering a small molecule called IPA-3, significantly slows the progression of cancer and forces cancerous cells to undergo apoptosis.
Researchers at ETH Zurich discovered that sulforaphane, a broccoli ingredient, increases the concentration of enzymes in colon cancer cells, making it more effective for chemotherapy. This natural compound can reduce medication doses and is non-toxic with no unwanted side effects.
A UC team created a new nanostructure that shows significantly higher properties for detecting and destroying cancerous cells, enabling targeted drug delivery. The discovery was made possible by complex calculations conducted by PhD student Zohre Gorunmez.
Researchers identified key proteins connecting genetic material to cell structures, enabling accurate DNA distribution during cell division. The findings resolve a longstanding puzzle in cell division and may provide insight into cancer susceptibility.
A recent study by MIT biologists found that cancer cells use amino acids to build new cell mass, contradicting the long-held assumption that glucose is the primary source. The largest contributors to cell mass were amino acids, making up 20-40% of total mass.
Scientists at St Jude Children's Research Hospital discovered a new pathway for mitochondrial cell death involving the BCL-2 ovarian killer protein. This mechanism is linked to cellular stress and may lead to new cancer treatments.
Researchers have discovered a key protein that drives blood cancer development and may prevent it with MCL-1 inhibitors. Seventy percent of human cancers have abnormally high levels of MYC, which forces cells into rapid growth.
Researchers at The Ottawa Hospital and University of Ottawa identified a compound called GSK-J4 that can kill a severe form of childhood leukemia. By targeting the TAL-1 gene, the compound stops cancer cell growth, showing promise for personalized treatment.
Researchers have discovered a trick used by lung cancer cells to hide from the immune system, specifically suppressing immunoproteasomes that signal T-cells to attack diseased cells. The study suggests it may be possible to enhance production of these proteins to override the cells' escape mechanism.
Brown University engineers developed a new technique to understand how cells move through complex tissues, building on mean deformation theory. The algorithm analyzed images of human neutrophils moving through collagen matrices, revealing differences in contractility and rotation between healthy and sepsis models.
Researchers found that cancerous mutations are linked to stiff tissues, where cells experience more nucleus deformation and damage. This constricted migration causes molecular damage, leading to genomic instability and increased mutation rates.
Researchers found that Porphyromonas gingivalis is present in 61% of patients with esophageal squamous cell carcinoma (ESCC), a type of esophageal cancer. The bacteria was only detected in 12% of tissues adjacent to the cancerous cells, suggesting it may be a risk factor for ESCC.
UT Southwestern Medical Center researchers have designed a powerful 3-D microscope capable of creating high-resolution images of living cancer cells in controlled microenvironments. The new approach enables detailed study of cell interactions with their environment, accelerating discovery in biology.
Researchers at Ohio State University have developed a DNA 'Trojan horse' that can deliver cancer drugs into resistant cells, effectively killing them. The capsule made of folded up DNA hides the invading force, allowing it to bypass cell defenses and accumulate in cancer cells.
Researchers at the University of Southern California have developed a method for manufacturing nanoparticles on a large scale, using microfluidics technology. This innovation enables the cost-effective production of gold nanoparticles with unique properties, making them ideal for applications in medicine and other fields.
A new therapeutic pathway has been discovered to keep cancer cells dormant, offering hope for treating osteosarcoma and potentially other cancers. Researchers found three microRNAs that can inhibit the growth of cancer cells, allowing them to remain asymptomatic and manageable.
Researchers at Hiroshima University have linked stomach (gastric) and prostate cancer to a specific type of DNA called T-UCRs. The study identifies a potential regulatory pathway of stomach (gastric) cancer, providing new insights into cancer genetics.
Researchers have discovered how nutlins work by activating the body's natural cancer-suppressing mechanism, gene P53, and triggering programmed cell death in blood cancer cells. This breakthrough paves the way for more precise and personalized medical treatments for cancer.
Scientists have observed ring-shaped pores in the Bax protein, which perforates mitochondrial membranes and initiates cell death. This discovery may lead to a better understanding of apoptosis and its role in preventing cancer.
Researchers found that NK cells produce VEGF-A to promote tumor growth when STAT5 is inhibited. This discovery challenges the use of STAT5 inhibitors in cancer treatment, which could have unintended consequences for patients.
Researchers link NSAIDs with ruthenium and osmium ions to destroy cancer cells, while leaving most normal cells alone in lab tests. The combination shows promise as an effective treatment for ovarian cancer and potentially reduces side effects.
Researchers use light to measure the 'big stretch' in spider silk proteins, shedding light on biological events such as cancer metastasis. The tool allows for real-time measurement of forces acting on proteins in live cells.
A new study by Texas Tech University Health Sciences Center El Paso found that a compound in neem leaves can stop pancreatic cancer growth and metastasis without harming normal cells. The researchers observed a 70% reduction in cancer cell migration and invasion, as well as an 80% drop in cancer cell colonies.
Researchers discovered a novel mechanism by which adenovirus protein E4orf4 inhibits the DNA damage response, improving viral replication. This finding provides insight into the virus's ability to infect immunocompromised patients and may lead to new cancer therapies.
A new method called 'ADPr-ChAP' allows researchers to identify chromatin sites modified by ADP-ribosylation in response to cell stress, enabling a better understanding of the cellular stress reaction. This breakthrough could lead to new ways of intervening in disease-making processes such as chronic inflammation and cancer.
Researchers at UT Southwestern Medical Center developed a nanoparticle therapy that combines LDL and fish oil to preferentially kill primary liver cancer cells. The approach shows significant anti-cancer activity, with over 80% of tumor cells dying, and holds promise for potentially treating other cancers.
Researchers at St. Jude Children's Research Hospital have discovered a unique mechanism underlying Ph-like ALL, a particularly aggressive form of acute lymphoblastic leukemia. The findings reveal that chromosomal rearrangements lead to the activation of a truncated EPOR gene, driving white blood cells to proliferate out of control.
A new study reveals that chromosomes undergo a transformation in senescent cells, with some genes moving into more restrictive compartments. This change affects gene expression and may have implications for health conditions such as aging and cancer.
Researchers at Texas A&M University use optogenetics to control immune cells, instructing them to kill cancerous tumor cells. This method allows for fine-tuning of calcium-dependent actions of immune cells to fight against invading pathogens or tumor cells.
Researchers found that deprivation of cystine triggers necrosis in renal cell carcinoma cells, leading to cell death and delayed tumor growth. This approach may offer a new therapeutic strategy for treating this aggressive form of kidney cancer.
A small minority of cancer cells in neuroendocrine tumors contribute to the overall growth and metastasis of the tumor. The discovery sheds light on the different functions of cancer cells, with implications for understanding tumor aggression.
A new class of drug, YELIVA™ (ABC294640), has shown promise in slowing the growth of castration-resistant prostate cancer cells by inhibiting the sphingolipid pathway. The study found that treatment with YELIVA™ increased dihydroceramide levels and reduced expression of key oncogenes.
Researchers have identified a new mechanism governing DNA repair in the presence of certain class of histone deacetylases. This discovery has implications for cancer treatment and could lead to optimization of clinical use of HDAC inhibitors.